Floatz logo

Ropidoxuridine

Stage III Small Intestinal Cancer AJCC v7

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Stage III Small Intestinal Cancer AJCC v7 cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
Cancer Research UK
Phase 2BB
VINCRISTINE SULFATE
Cancer Research UK
Phase 2BB
FILGRASTIM
Cancer Research UK
Phase 2BB
PREDNISONE TABLETS
City of Hope Medical Center
Phase 2B

View all 50 →

Same molecule, other indications

Ropidoxuridine is also rated in:

IDH-wildtype glioblastomaDormant
CC
Indicative ·
47 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CC
Indicative ·
41 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →